Company / Operating Income
CHINA PHARMA HOLDINGS, INC. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$3.2M
FY2025
5-year range
-$3.5M / -$2.6M
FY2021-FY2025
Trend
-17.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has fluctuated over the past 10 years, ranging from -$20M in FY2020 to -$3M in FY2021.
Based on SEC 10-K filings.
-$3M in FY2025.
Declined from -$3M to -$3M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income decreased 17.7% year-over-year.
- Peak operating income was recorded in FY2021.
- Lowest operating income in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -0.44 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.2M | -17.7% |
| FY2024 | -$2.8M | +0.0% |
| FY2023 | -$2.8M | +22.5% |
| FY2022 | -$3.5M | -37.6% |
| FY2021 | -$2.6M | +87.4% |
| FY2020 | -$20.4M | -95.3% |
| FY2019 | -$10.4M | +44.1% |
| FY2018 | -$18.7M | -129.0% |
| FY2017 | -$8.2M | +43.0% |
| FY2016 | -$14.3M | +63.1% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026